SMLE respiratory medicine questions

Smoking cessation is the single most effective intervention to slow the accelerated decline in FEV1 seen in COPD and is the only intervention proven to alter the natural history of the disease. Pharmacotherapy (bronchodilators, inhaled corticosteroids) improves symptoms and reduces exacerbations but does not slow the rate of lung function decline to the same degree. Pulmonary rehabilitation and vaccination improve quality of life and reduce morbidity but do not match the mortality and decline benefit of quitting smoking. All patients with COPD who smoke should be offered behavioral counseling and pharmacologic aids (nicotine replacement, varenicline, bupropion) at every visit.

• B. Improves symptoms and exacerbation frequency but does not slow the decline in lung function.
• C. Reduces exacerbation-related morbidity and mortality but does not alter the rate of FEV1 decline.
• D. Improves exercise capacity and quality of life but has no proven effect on the rate of lung function decline.

For a previously healthy outpatient with no comorbidities, oral amoxicillin is the preferred first-line empirical therapy for community-acquired pneumonia because it provides reliable coverage against Streptococcus pneumoniae, the most common bacterial cause. Guidelines reserve respiratory fluoroquinolones or macrolide/beta-lactam combinations for patients with comorbidities or risk factors for drug-resistant pathogens. Intravenous therapy is unnecessary in a hemodynamically stable patient who can tolerate oral intake and does not meet criteria for hospitalization. Clindamycin lacks reliable activity against the common typical pathogens causing CAP and is not a first-line choice.

• A. Intravenous therapy is unnecessary for a hemodynamically stable outpatient who can take oral medication.
• C. Clindamycin does not reliably cover Streptococcus pneumoniae and is not standard empirical therapy for CAP.
• D. Fluoroquinolones are reserved for patients with comorbidities, resistance risk factors, or beta-lactam allergy, not first-line in healthy adults.

Mycoplasma pneumoniae classically causes atypical pneumonia in young adults living in close quarters (dormitories, military barracks), presenting with a gradual onset of dry cough, headache, and constitutional symptoms with relatively mild auscultatory findings compared to the degree of radiographic infiltrate. Chest imaging characteristically shows bilateral, patchy, reticulonodular or interstitial infiltrates rather than a lobar consolidation. Outbreaks in shared living settings are typical because Mycoplasma spreads through close contact over a prolonged incubation period. Streptococcus pneumoniae typically causes a more acute illness with lobar consolidation and more pronounced findings on examination.

• A. Causes a more severe, often cavitating pneumonia, frequently post-influenza, not a mild walking pneumonia picture.
• C. Typically causes acute lobar consolidation with prominent examination findings, not a mismatch between mild signs and diffuse interstitial infiltrates.
• D. Classically causes cavitary, necrotizing pneumonia in alcoholics or diabetics with currant-jelly sputum, not this presentation.

Ventilator-associated pneumonia occurring after 48 hours of mechanical ventilation in a unit with high rates of methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas requires empirical broad-spectrum coverage against both organisms until cultures are available. Vancomycin (or linezolid) covers MRSA, while an antipseudomonal beta-lactam such as piperacillin-tazobactam covers Pseudomonas and other gram-negative organisms. Monotherapy or oral regimens are inadequate for this severity of nosocomial infection and the resistance risk profile. Therapy should be narrowed once culture and sensitivity results are available, following antimicrobial stewardship principles.

• A. A single oral fluoroquinolone does not reliably cover MRSA and is inadequate monotherapy for VAP in a high-resistance setting.
• B. Azithromycin alone lacks activity against MRSA and Pseudomonas and is not appropriate empirical monotherapy for VAP.
• D. Oral therapy and this agent alone do not provide adequate coverage for MRSA or multidrug-resistant Pseudomonas in a ventilated ICU patient.

Lung abscess following witnessed aspiration in a patient with impaired consciousness is typically caused by mixed anaerobic and microaerophilic oral flora (such as Peptostreptococcus, Fusobacterium, and Prevotella species) along with aerobic organisms, reflecting the dependent lung segments where aspirated material settles, classically the posterior segment of the right upper lobe or superior segment of the right lower lobe in the supine position. Treatment is prolonged antibiotic therapy, often for several weeks, with agents such as ampicillin-sulbactam or clindamycin that have good anaerobic coverage, continued until radiographic resolution or significant improvement. Surgery is reserved for abscesses that fail to respond to antibiotics, are very large, or cause complications such as massive hemoptysis. Postural drainage occurs with antibiotics but is not a sole treatment.

• A. Bronchodilators do not treat the underlying infective process causing the abscess.
• B. Surgery is reserved for cases that fail prolonged antibiotic therapy or develop complications, not first-line management.
• D. A single dose of penicillin is inadequate for an anaerobic lung abscess, which requires weeks of therapy.

This pleural fluid meets criteria for a complicated parapneumonic effusion or empyema requiring chest tube drainage: pH less than 7.2, glucose less than 2.2 mmol/L (40 mg/dL), grossly turbid or frankly purulent fluid, and a positive Gram stain or culture all indicate the need for drainage rather than antibiotics alone. Lactate dehydrogenase above 1000 U/L supports an exudative, inflammatory process consistent with empyema. Antibiotics alone are insufficient once these biochemical and microbiological criteria are met, because the infected fluid and fibrin deposition impair antibiotic penetration and resolution. Pleurodesis is used for recurrent malignant effusions, not as initial management of an acute empyema.

• A. Discharge is inappropriate given the need for drainage of an infected pleural space and continued inpatient monitoring.
• C. Antibiotics alone are inadequate once pH, glucose, and Gram stain criteria for a complicated effusion are met; drainage is required.
• D. Pleurodesis is used for recurrent effusions after drainage, not as an initial treatment for acute empyema.

GeneXpert MTB/RIF is a nucleic acid amplification test that detects Mycobacterium tuberculosis DNA and rifampicin resistance mutations within about two hours, making it the preferred initial diagnostic test in a patient with a high pretest probability of active TB. It has higher sensitivity than smear microscopy and provides resistance information that culture alone would take weeks to deliver. Smear microscopy is useful for assessing infectiousness but has lower sensitivity and does not detect resistance. The tuberculin skin test reflects exposure or latent infection, not active disease, and is not useful in symptomatic patients with radiographic findings.

• A. Smear microscopy alone has lower sensitivity and does not provide information on rifampicin resistance.
• C. The tuberculin skin test cannot distinguish active from latent infection and is not used to diagnose active disease.
• D. Culture is the gold standard for confirmation and drug susceptibility but takes weeks, which delays timely treatment decisions.

Reactivation (post-primary) tuberculosis characteristically involves the apical and posterior segments of the upper lobes, where higher oxygen tension favors mycobacterial growth, producing cavitation and fibronodular infiltrates. Lower lobe consolidation is more typical of bacterial community-acquired pneumonia. A solitary nodule with popcorn calcification suggests a hamartoma, a benign tumor unrelated to TB. Diffuse ground-glass opacities with a halo sign are more suggestive of fungal infections such as invasive aspergillosis.

• A. A halo sign with ground-glass opacities is typically associated with invasive fungal infection such as aspergillosis.
• C. Lower lobe consolidation with air bronchograms is characteristic of typical bacterial pneumonia, not reactivation TB.
• D. Popcorn calcification is a classic benign feature of a pulmonary hamartoma, not tuberculosis.

The standard first-line regimen for drug-susceptible pulmonary tuberculosis is a 2-month intensive phase with rifampicin, isoniazid, pyrazinamide, and ethambutol (RIPE), followed by a 4-month continuation phase with rifampicin and isoniazid, for a total of 6 months. The intensive phase rapidly reduces bacillary load and prevents resistance, while the continuation phase eliminates residual organisms. Omitting pyrazinamide and ethambutol from the start risks resistance, and continuing all four drugs for the full 6 months is unnecessarily toxic and not guideline-recommended.

• A. This regimen omits rifampicin, which is a cornerstone first-line agent, and uses an inappropriate duration.
• C. Continuing all four drugs for the entire 6 months increases toxicity without added benefit over the standard phased regimen.
• D. This two-drug regimen lacks the intensive phase drugs needed to rapidly reduce bacillary burden and prevent resistance.

Isoniazid causes peripheral neuropathy by increasing renal excretion of pyridoxine and inhibiting pyridoxine-dependent enzymes needed for neurotransmitter and myelin synthesis, leading to functional vitamin B6 deficiency. Co-administration of pyridoxine, especially in patients at higher risk such as those with malnutrition, alcoholism, diabetes, pregnancy, or HIV, prevents this complication. Folic acid, vitamin B12, and thiamine deficiencies are not specifically linked to isoniazid's mechanism of neurotoxicity.

• B. Thiamine deficiency causes beriberi and Wernicke encephalopathy, not isoniazid-induced neuropathy.
• C. Vitamin B12 deficiency causes a different pattern of neuropathy and is not related to isoniazid metabolism.
• D. Folic acid deficiency is not the mechanism underlying isoniazid-induced neuropathy.

Ethambutol can cause dose-related optic neuritis, presenting with decreased visual acuity, central scotomas, and loss of red-green color discrimination due to toxic effects on the optic nerve. Baseline and periodic visual acuity and color vision testing (such as Ishihara charts) are recommended throughout treatment, and the drug should be discontinued promptly if symptoms occur since changes may be irreversible if missed. Isoniazid is associated with hepatotoxicity and neuropathy, not visual disturbance. Pyrazinamide causes hyperuricemia and hepatotoxicity, and rifampicin is not associated with ototoxicity.

• B. Isoniazid is associated with hepatotoxicity and peripheral neuropathy, not visual disturbances.
• C. Rifampicin is not associated with ototoxicity; it causes hepatotoxicity and orange discoloration of body fluids.
• D. Pyrazinamide causes hyperuricemia and arthralgia, not optic neuritis.

In a patient with a clinical picture suggestive of idiopathic pulmonary fibrosis (older age, progressive dyspnea, bibasilar crackles, clubbing, negative connective tissue disease serology), high-resolution CT is the key investigation. A definite usual interstitial pneumonia pattern on HRCT, characterized by subpleural and basal predominant reticular abnormality with honeycombing and traction bronchiectasis without features suggesting an alternative diagnosis, is sufficient to confirm IPF without the need for lung biopsy. Surgical biopsy is reserved for cases with an indeterminate or atypical HRCT pattern. Bronchoalveolar lavage and walk tests do not establish the diagnosis.

• A. Biopsy is only needed when HRCT findings are atypical or inconclusive, not as the initial diagnostic test.
• B. BAL differential helps exclude other ILDs but is not diagnostic of IPF.
• C. This test assesses functional impairment and prognosis but does not establish the diagnosis.

Bilateral hilar and mediastinal lymphadenopathy with biopsy-proven non-caseating (non-necrotizing) granulomas, after exclusion of infectious causes by negative cultures and stains, is the classic presentation of sarcoidosis. Hypercalcemia occurs due to unregulated extrarenal production of 1,25-dihydroxyvitamin D by activated macrophages within granulomas. Tuberculosis typically shows necrotizing (caseating) granulomas and would usually show organisms or be culture positive. Hodgkin lymphoma would show Reed-Sternberg cells rather than granulomas alone, and berylliosis requires a specific occupational beryllium exposure history that is absent here.

• A. Lymphoma biopsy shows malignant lymphoid cells such as Reed-Sternberg cells, not isolated non-caseating granulomas.
• B. Berylliosis requires a history of beryllium exposure, which is not mentioned in this case.
• C. TB granulomas are typically necrotizing/caseating, and cultures and stains are negative here.

Recurrent respiratory symptoms temporally related to exposure to an avian antigen, with symptom resolution on avoidance, ground-glass opacities and centrilobular nodules with air trapping on CT, and positive serum precipitins, are characteristic of hypersensitivity pneumonitis (bird breeder's lung). This is an immune-mediated reaction (type III and IV hypersensitivity) to repeatedly inhaled organic antigens. Allergic bronchopulmonary aspergillosis occurs in asthmatics or those with cystic fibrosis and is associated with central bronchiectasis and elevated IgE/Aspergillus sensitization, not relevant exposure history here. Community-acquired pneumonia does not show this exposure-related recurrent pattern, and chronic eosinophilic pneumonia is not linked to a specific antigen exposure.

• B. Chronic eosinophilic pneumonia lacks a clear exposure-dependent trigger and precipitin positivity.
• C. CAP does not recur in a pattern linked to specific environmental exposure and resolve with avoidance.
• D. ABPA is associated with asthma or cystic fibrosis and elevated IgE to Aspergillus, not avian antigen exposure.

Prolonged occupational exposure to crystalline silica dust, as occurs in sandblasting and stone cutting, causes silicosis. The radiologic hallmark is small rounded nodular opacities predominantly in the upper lung zones, with eggshell calcification of hilar lymph nodes being a characteristic although not universal finding. Asbestosis typically shows lower zone linear/reticular opacities with pleural plaques rather than upper zone nodules. Coal worker's pneumoconiosis can produce similar nodular opacities but is linked to coal mining exposure, not sandblasting, and byssinosis is a reversible airway disease from cotton dust exposure without these radiologic findings.

• B. This occurs with coal mining exposure, not sandblasting or stone-cutting work.
• C. Asbestosis causes lower zone reticular opacities and pleural plaques, not upper zone rounded nodules with eggshell calcification.
• D. Byssinosis is caused by cotton dust and presents as a reversible airflow obstruction, not nodular fibrotic opacities.

A restrictive ventilatory defect is characterized by a proportionate reduction in FVC and FEV1 with a normal or increased FEV1/FVC ratio (here 0.89, above the normal threshold of 0.70), along with a reduced total lung capacity, confirming true restriction rather than air trapping. The reduced DLCO reflects the impaired gas exchange typical of interstitial lung disease due to loss of alveolar-capillary surface area. An obstructive defect would show a reduced FEV1/FVC ratio with normal or increased lung volumes. A mixed pattern requires evidence of both reduced ratio and reduced lung volumes, which is not present here.

• B. Obstruction is defined by a reduced FEV1/FVC ratio, which is normal/increased here, not reduced lung volumes with a preserved ratio.
• C. Both FVC and TLC are reduced, confirming a true restrictive defect, not isolated gas exchange impairment.
• D. A mixed defect requires a reduced FEV1/FVC ratio together with reduced lung volumes; the ratio here is normal.

In patients with a high clinical probability of pulmonary embolism by Wells score, D-dimer testing should not be used because a negative result does not reliably exclude PE in this group, and a positive result adds no diagnostic value. The appropriate next step is to proceed directly to CT pulmonary angiography (or anticoagulate first if imaging will be delayed, then confirm with imaging). D-dimer is useful mainly in low or intermediate probability patients to help rule out PE without imaging. V/Q scanning is reserved for patients with contraindications to CT contrast, such as renal impairment or contrast allergy.

• B. Anticoagulation without confirmatory imaging is not appropriate as the sole management step when imaging is readily available.
• C. V/Q scan is reserved as an alternative when CT pulmonary angiography is contraindicated, not as the first-line test.
• D. D-dimer testing is not useful in high pretest probability patients, as a negative result does not exclude PE reliably in this group.

In patients with high clinical probability of PE and normal renal function, CT pulmonary angiography (CTPA) is the diagnostic test of choice because it directly visualizes emboli in the pulmonary arteries with high sensitivity and specificity, and simultaneously evaluates alternative diagnoses. D-dimer has no role once pretest probability is high, since a negative result does not reliably exclude PE in this group. V/Q scanning is reserved for patients with contraindications to CT contrast (e.g., renal impairment, contrast allergy) or pregnancy. This patient has normal renal function, making CTPA both feasible and preferred.

• A. D-dimer is not used to confirm PE in high-probability patients; it is a rule-out test used in low-probability cases.
• B. Lower limb ultrasound may support the diagnosis if positive but cannot confirm or exclude PE itself.
• C. V/Q scan is an alternative when CT contrast is contraindicated, not the first-line test with normal renal function.

For a first unprovoked (idiopathic) PE, current guidelines recommend extended (indefinite) anticoagulation beyond the initial 3 months, because the risk of recurrence after stopping treatment is substantial (approximately 10% in the first year and continuing thereafter) and exceeds the risk of major bleeding in most patients. Anticoagulation should be continued as long as the bleeding risk remains acceptable, with periodic reassessment of risk-benefit balance, patient preference, and use of bleeding risk scores. A fixed 3-month course is appropriate for provoked PE with a reversible risk factor, not for unprovoked events. Stopping after only 6 weeks or omitting anticoagulation would leave the patient at unacceptably high risk of recurrent, potentially fatal, thromboembolism.

• A. Omitting anticoagulation would leave the patient at high risk of recurrent, potentially fatal, embolism.
• C. 6 weeks is far shorter than the minimum recommended duration for any confirmed PE.
• D. A 3-month fixed course is appropriate for provoked PE with a clear transient risk factor, not for unprovoked PE.

This patient has massive (high-risk) PE with persistent hypotension despite fluid resuscitation, a dilated hypokinetic right ventricle, and hypoxemia, all indicating obstructive shock from right ventricular failure. In the absence of absolute contraindications such as active bleeding or recent intracranial hemorrhage, systemic thrombolysis is indicated to rapidly dissolve the clot burden and reverse right ventricular failure, reducing mortality. Heparin alone does not actively lyse clot and is insufficient as monotherapy in hemodynamically unstable PE. IVC filters prevent further embolization but do not treat the existing obstruction, and oral anticoagulants have no role in the acute unstable phase.

• B. Oral anticoagulants have no role in acute hemodynamically unstable PE and lack the rapid onset required.
• C. Heparin alone prevents clot propagation but does not rapidly dissolve the obstructing thrombus needed in hemodynamic instability.
• D. An IVC filter prevents future emboli but does not address the current life-threatening obstruction.

Cor pulmonale is right ventricular hypertrophy and failure secondary to chronic lung disease causing pulmonary hypertension, without primary left heart disease. Key distinguishing features from left ventricular failure include signs of isolated right-sided overload, elevated jugular venous pressure, a parasternal (right ventricular) heave, loud P2, hepatomegaly, and peripheral edema, in the absence of pulmonary crackles or orthopnea that would suggest pulmonary venous congestion from left heart failure. Fine basal crackles, an S3 with a displaced apex, and bilateral effusions are more typical of left ventricular failure with pulmonary venous hypertension. The combination in this patient reflects pure right heart strain driven by chronic hypoxemic lung disease.

• A. Basal crackles suggest pulmonary edema from left heart failure, not isolated right heart failure.
• B. Pleural effusions can occur in both conditions and are not specific for right ventricular failure.
• D. A displaced apex beat with S3 suggests left ventricular dilation and failure, not isolated right heart disease.

Light's criteria classify a pleural effusion as an exudate if any one of the following is present: pleural fluid-to-serum protein ratio greater than 0.5, pleural fluid-to-serum LDH ratio greater than 0.6, or pleural fluid LDH greater than two-thirds the upper limit of normal serum LDH. This patient's protein ratio of 0.58 already exceeds 0.5, and the LDH ratio of 1.22 exceeds 0.6, so both criteria classify the fluid as exudative, meeting the rule that satisfying any single criterion suffices. Exudative effusions point toward causes such as infection, malignancy, or inflammatory disease rather than conditions causing transudates like heart failure or cirrhosis. Further workup (cytology, cultures, adenosine deaminase) should be directed at identifying the exudative cause.

• B. Light's criteria already classify this fluid definitively; cholesterol measurement is not required when the criteria are met.
• C. An LDH ratio of 1.22 exceeds the 0.6 threshold, so this criterion also indicates an exudate, not a transudate.
• D. A protein ratio of 0.58 exceeds the 0.5 threshold, so this criterion actually indicates an exudate.

This patient has clinical signs of tension pneumothorax: hypotension, tachycardia, tracheal deviation away from the affected side, hyperresonance, and absent breath sounds, with hypoxia and distended neck veins indicating obstructive shock. Tension pneumothorax is a clinical diagnosis and a medical emergency, so treatment must not be delayed for imaging. Immediate needle decompression (or finger thoracostomy) in the second intercostal space, midclavicular line (or 4th/5th intercostal space, anterior axillary line) on the affected side converts the tension pneumothorax to a simple one and restores venous return and cardiac output. Definitive management with a chest tube follows decompression.

• A. Imaging delays life-saving treatment and is unnecessary when the diagnosis is clinically evident.
• B. Fluids alone do not relieve the mechanical obstruction to venous return caused by the tension pneumothorax.
• D. CT is not indicated in an unstable patient and would dangerously delay decompression.

This patient has an exudative pleural effusion (Light's criteria met) in the setting of a heavy smoking history, raising strong suspicion for malignancy. Pleural fluid cytology is the single best initial test for suspected malignant pleural effusion, with a diagnostic yield of 60-70% for adenocarcinoma, and it is far less invasive than pleural biopsy. If cytology is negative but suspicion remains high, image-guided or thoracoscopic pleural biopsy is the next step. Cytology directly identifies malignant cells and can also suggest the primary tumor type.

• A. Serum CEA is a nonspecific tumor marker and is not a diagnostic test for malignant effusion.
• B. Adenosine deaminase is used to support a diagnosis of tuberculous pleuritis, not malignancy.
• D. Gram stain and culture are used to evaluate for infectious causes such as empyema, not malignancy.

Re-expansion pulmonary edema occurs when a chronically collapsed lung is rapidly re-expanded, as can happen after fast drainage of a large or long-standing pneumothorax or effusion. It is thought to result from increased capillary permeability and reperfusion injury in the previously collapsed lung tissue, combined with surfactant dysfunction. Risk is reduced by controlled, gradual drainage and limiting negative intrapleural pressure during chest tube placement. Management is supportive, with oxygen and, if needed, mechanical ventilation.

• A. Bronchopleural fistula presents with a persistent air leak, not acute pulmonary edema after drainage.
• B. Pulmonary embolism would not typically cause new opacities confined to the just re-expanded lung.
• D. Recurrent tension pneumothorax would show absent breath sounds and hyperresonance, not new opacities on the re-expanded side.

This patient has the syndrome of inappropriate antidiuretic hormone secretion (SIADH), evidenced by hyponatremia with inappropriately concentrated urine in a euvolemic patient without thyroid or adrenal dysfunction. SIADH is a well-recognized paraneoplastic syndrome associated with small cell lung carcinoma, caused by ectopic secretion of antidiuretic hormone from the tumor cells. Small cell carcinoma, a neuroendocrine tumor, is also associated with ectopic ACTH secretion causing Cushing syndrome and with Lambert-Eaton myasthenic syndrome. Squamous cell carcinoma is more classically associated with hypercalcemia from parathyroid hormone-related peptide.

• B. Adenocarcinoma is not classically associated with SIADH; it is more linked to hypertrophic osteoarthropathy.
• C. Carcinoid tumors typically cause carcinoid syndrome with flushing and diarrhea, not SIADH.
• D. Squamous cell carcinoma is associated with hypercalcemia via PTH-related peptide, not SIADH.

This presentation is classic for a Pancoast tumor, a lung cancer arising at the apex that invades the brachial plexus (C8-T1 distribution, explaining ulnar-side arm pain and intrinsic hand weakness) and the sympathetic chain, producing Horner syndrome (miosis, ptosis, anhidrosis). The combination of an apical mass on imaging with these clinical findings is diagnostic of local tumor invasion rather than an incidental neurological condition. Most Pancoast tumors are non-small cell lung cancers, usually squamous cell or adenocarcinoma. MRI of the chest and brachial plexus is used to assess the extent of invasion for staging and surgical planning.

• A. Cervical disc herniation does not explain the apical lung mass or Horner syndrome.
• C. Multiple sclerosis does not cause Horner syndrome with an apical lung mass and brachial plexus pattern pain.
• D. Thoracic outlet syndrome does not produce Horner syndrome and is not associated with an apical mass.

This patient has superior vena cava (SVC) obstruction syndrome, an oncologic emergency most commonly caused by extrinsic compression or invasion of the SVC by a mediastinal mass, frequently lung cancer. The classic findings are facial and neck swelling, dilated chest wall collateral veins, and conjunctival suffusion, worsened by recumbency due to increased venous pressure above the obstruction. Management includes elevation of the head, oxygen, and urgent oncologic treatment (chemotherapy, radiotherapy, or SVC stenting depending on tumor type and severity), often with tissue diagnosis obtained first if the patient is stable enough. Severe airway compromise or significant cerebral edema requires urgent intervention.

• B. Pulmonary embolism presents with acute dyspnea and chest pain, not facial swelling and dilated chest wall veins.
• C. Cardiac tamponade presents with hypotension, muffled heart sounds, and distended neck veins, but not facial edema with chest wall collaterals.
• D. Tracheal compression would cause stridor and airway symptoms rather than facial swelling with venous collaterals.

Polysomnography is the gold-standard test for diagnosing obstructive sleep apnea. It records sleep stages, airflow, respiratory effort, oxygen saturation, and limb movements, allowing calculation of the apnea-hypopnea index (AHI), which quantifies disease severity (mild 5-15, moderate 15-30, severe >30 events/hour). This patient's clinical picture (snoring, witnessed apneas, daytime somnolence, obesity, increased neck circumference) is classic for OSA and warrants confirmatory testing before starting treatment. Home sleep apnea testing (limited channel) can be used in select low-risk patients but is less comprehensive than full polysomnography.

• B. Pulmonary function tests assess lung mechanics and are used to evaluate obstructive or restrictive lung disease, not sleep-related breathing disorders.
• C. Arterial blood gas reflects daytime gas exchange and does not capture nocturnal respiratory events characteristic of OSA.
• D. Pulse oximetry alone detects desaturation but cannot distinguish apnea type or calculate the AHI needed for diagnosis and severity grading.

Continuous positive airway pressure (CPAP) is first-line therapy for moderate to severe obstructive sleep apnea. It splints the upper airway open during sleep, preventing collapse and recurrent apneic/hypopneic events, which reduces daytime sleepiness, improves quality of life, and lowers cardiovascular risk. Weight loss and lifestyle modification are adjuncts but not substitutes for CPAP in severe disease. Surgical and oral appliance options are reserved for CPAP intolerance or mild disease.

• A. Mandibular advancement devices are better suited for mild to moderate OSA or for patients who cannot tolerate CPAP.
• B. Uvulopalatopharyngoplasty is a second-line surgical option considered only after failure of or intolerance to CPAP.
• C. Modafinil may be used for residual daytime sleepiness despite adequate CPAP use, not as primary therapy for the underlying apnea.

Type 2 (hypercapnic) respiratory failure is defined by PaCO2 greater than 45 mmHg with hypoxemia, reflecting alveolar hypoventilation, commonly seen in COPD exacerbations, CNS depression, or neuromuscular weakness. This patient has hypercapnia (PaCO2 68 mmHg) with concurrent hypoxemia (PaO2 52 mmHg), and the elevated bicarbonate indicates renal compensation for chronic CO2 retention. Type 1 failure involves hypoxemia with normal or low PaCO2 due to a ventilation-perfusion mismatch, which does not fit this picture. Recognizing type 2 failure guides the need for ventilatory support rather than oxygen alone, since high-flow oxygen can worsen hypercapnia in some COPD patients.

• B. Type 1 respiratory failure features hypoxemia with normal or low PaCO2, not the hypercapnia seen here.
• C. The primary disturbance is respiratory (hypoventilation causing CO2 retention), not a primary metabolic process; the elevated HCO3- is compensatory.
• D. The pH is acidotic, not alkalotic, excluding a compensated alkalosis.

The Berlin definition of ARDS requires acute onset (within 1 week of a known clinical insult), bilateral opacities on chest imaging not fully explained by effusion, collapse, or nodules, respiratory failure not fully explained by cardiac failure or fluid overload, and a PaO2/FiO2 ratio of 300 mmHg or less with PEEP of at least 5 cmH2O. This patient's PaO2/FiO2 ratio is 68/0.5 = 136 mmHg, meeting criteria for moderate ARDS, in the setting of a recognized risk factor (severe pancreatitis) with a normal echocardiogram excluding cardiogenic causes. The combination of timing, bilateral infiltrates, exclusion of cardiac cause, and oxygenation criteria is diagnostic.

• A. There is no clinical or radiologic evidence (e.g., focal consolidation, fever with purulent sputum) pointing to pneumonia as the primary process.
• C. Pulmonary embolism would not typically present with bilateral diffuse infiltrates in this context, and no evidence supports infarction.
• D. Cardiogenic edema is excluded by the normal echocardiogram showing no volume overload or ventricular dysfunction.

Lung-protective ventilation in ARDS uses low tidal volumes of 4-8 mL/kg (typically starting at 6 mL/kg) of ideal (predicted) body weight, with plateau pressure kept below 30 cmH2O, to minimize ventilator-induced lung injury from overdistension and barotrauma. This strategy, established by the landmark ARMA trial and endorsed by current ARDS guidelines, reduces mortality compared with traditional higher tidal volumes. Permissive hypercapnia and mild respiratory acidosis are often accepted as a trade-off for lung protection. Tidal volume is calculated based on ideal body weight (derived from height and sex), not actual body weight, to avoid overdistension in obese patients.

• A. Tidal volume should be calculated using ideal body weight, not actual body weight, and plateau pressure must still be monitored and limited.
• B. Tidal volumes this high and plateau pressures up to 40 cmH2O increase the risk of barotrauma and ventilator-induced lung injury, contrary to lung-protective principles.
• D. Permissive hypercapnia is an accepted and often necessary consequence of lung-protective ventilation, not something to be avoided at all costs.

Acute epiglottitis presents with abrupt high fever, severe sore throat, dysphagia, drooling, a muffled 'hot potato' voice, and the classic tripod position with neck extension to maximize airway patency, often in unvaccinated children (reflecting lack of protection against Haemophilus influenzae type b). It typically lacks a preceding viral prodrome of cough and coryza, distinguishing it from croup. Croup usually has a gradual onset with a barking cough, hoarseness, and low-grade fever following coryzal symptoms, and is far less toxic in appearance. Direct visualization of the oropharynx should be avoided in suspected epiglottitis, as it can precipitate complete airway obstruction.

• A. Bacterial tracheitis usually follows a viral prodrome with cough and presents with purulent secretions rather than the drooling and tripod positioning seen here.
• B. Croup typically develops gradually after coryzal symptoms, with a barking cough and hoarse voice, and children appear less toxic than in this case.
• C. Retropharyngeal abscess typically causes neck stiffness, torticollis, and odynophagia, but drooling with tripod positioning and abrupt severe toxicity are more typical of epiglottitis.

Intramuscular epinephrine, given in the anterolateral thigh, is the first-line and most critical treatment for anaphylaxis with airway compromise, hypotension, and respiratory distress. It acts rapidly via alpha-1 receptor-mediated vasoconstriction (reversing hypotension and mucosal edema) and beta-2 receptor-mediated bronchodilation, while also stabilizing mast cells to reduce further mediator release. Delay in epinephrine administration is associated with increased mortality in anaphylaxis, so it must be given immediately rather than after other adjunctive therapies. Antihistamines, corticosteroids, and bronchodilators are useful adjuncts but do not address the life-threatening vasodilation and airway edema as rapidly or effectively as epinephrine.

• B. Nebulized bronchodilators help bronchospasm but do not address the hypotension or angioedema, and are not a substitute for epinephrine.
• C. Corticosteroids have delayed onset of action and are used as an adjunct to prevent biphasic reactions, not as the immediate life-saving step.
• D. Oral antihistamines have slow onset and are inadequate for a life-threatening reaction with airway obstruction and shock.

The sweat chloride test is the gold-standard diagnostic test for cystic fibrosis, measuring chloride concentration in sweat via pilocarpine iontophoresis. A chloride concentration of 60 mmol/L or greater on two separate occasions is diagnostic, reflecting the underlying defect in the CFTR chloride channel. This child's presentation of recurrent respiratory infections, failure to thrive, and steatorrhea (from pancreatic insufficiency) is classic for cystic fibrosis. Chest CT may show bronchiectasis in established disease but is not diagnostic, while fecal elastase assesses pancreatic exocrine function as a complication rather than confirming the underlying diagnosis.

• B. Chest CT can reveal bronchiectasis and other structural lung changes in established cystic fibrosis but does not establish the underlying diagnosis.
• C. Nasal nitric oxide is low in primary ciliary dyskinesia, a differential diagnosis, but is not the diagnostic test for cystic fibrosis.
• D. Fecal elastase is useful for assessing pancreatic exocrine insufficiency, a complication of cystic fibrosis, but is not the diagnostic test for the disease itself.

The clinical picture of chronic productive cough, recurrent infections, hemoptysis, clubbing, and coarse crackles combined with HRCT showing bronchial dilatation with lack of tapering, bronchial wall thickening, and visible bronchi near the pleura is diagnostic of bronchiectasis. Common underlying causes include post-infectious damage (childhood pneumonia, tuberculosis), cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, and allergic bronchopulmonary aspergillosis. HRCT is the imaging modality of choice because plain radiographs lack sensitivity for airway dilatation. Identifying bronchiectasis should prompt a search for a treatable underlying cause to guide specific therapy and prevent progression.

• B. Active tuberculosis typically shows cavitation, tree-in-bud nodularity, or upper lobe fibronodular change rather than diffuse bronchial dilatation, though old TB is a recognized cause of bronchiectasis.
• C. COPD causes airflow obstruction from emphysema and small airway disease but does not produce tram-track bronchial dilatation or copious daily purulent sputum with clubbing.
• D. Idiopathic pulmonary fibrosis presents with dry cough, fine crackles, and HRCT honeycombing with reticulation, not purulent sputum or bronchial dilatation.

Significant bronchodilator reversibility, defined as an increase in FEV1 of at least 12% and at least 200 mL from baseline after a short-acting bronchodilator, supports a diagnosis of asthma by demonstrating variable, reversible airflow obstruction. An increase of 350 mL and 14.6% meets both the absolute and relative thresholds. Smaller increases that fail either criterion, or a persistently fixed obstructive ratio, are more consistent with fixed airflow limitation as seen in COPD.

• A. A fixed ratio after bronchodilator suggests irreversible obstruction, which is atypical for asthma and more typical of COPD.
• C. An isolated FVC change without an FEV1 increase does not meet reversibility criteria.
• D. This change fails to meet both the 12% relative and 200 mL absolute thresholds required for significant reversibility.

When spirometry is unavailable, serial peak expiratory flow (PEF) measurements taken morning and evening over 1-2 weeks can demonstrate the diurnal variability characteristic of asthma. A PEF variability of more than 10% (using twice-daily readings) supports the diagnosis. This is a practical, low-cost tool recommended by GINA for primary care settings lacking spirometry. The other investigations do not assess variable airflow limitation and are not first-line diagnostic tools for asthma.

• A. CT chest is reserved for atypical presentations or suspected alternative diagnoses, not for routine asthma diagnosis.
• B. Arterial blood gas is used to assess severity during acute exacerbations, not to establish a diagnosis of asthma.
• D. The six-minute walk test assesses functional exercise capacity and is not a standard asthma diagnostic test.

Current GINA guidance no longer recommends short-acting beta-agonist (SABA)-only treatment for asthma, even in patients with infrequent symptoms, because SABA-only therapy is associated with a higher risk of severe exacerbations. As-needed low-dose inhaled corticosteroid-formoterol (such as budesonide-formoterol) provides both rapid symptom relief and anti-inflammatory treatment, lowering exacerbation risk compared with SABA alone. Formoterol's fast onset of action makes this combination suitable as a reliever, unlike other long-acting beta-agonists.

• A. Salmeterol has a slow onset of action and should never be used as a reliever, and a long-acting beta-agonist should never be given without an inhaled corticosteroid.
• B. Oral corticosteroids are reserved for exacerbations, not for routine as-needed symptom relief in mild asthma.
• C. SABA-only reliever therapy is discouraged by current GINA guidelines due to increased risk of severe exacerbations and lack of anti-inflammatory effect.

This patient has poorly controlled asthma despite confirmed good adherence and technique on low-dose ICS-formoterol, meeting criteria to step up therapy according to GINA. The preferred step-up option within the same maintenance-and-reliever (MART) strategy is to increase the inhaled corticosteroid-formoterol dose to medium, maintaining a single inhaler for both maintenance and relief. Before any step-up, adherence and technique must be confirmed, which has already been done here. Adding a second controller class is considered only if ICS-formoterol step-up is insufficient.

• A. Long-term oral corticosteroids are reserved for severe asthma uncontrolled on maximal inhaled therapy, not as an early step-up measure.
• B. Reverting to SABA-only therapy removes anti-inflammatory control and increases exacerbation risk, which is inappropriate given poor control.
• D. Leukotriene receptor antagonists are an alternative add-on step considered after optimizing ICS-formoterol dose, not the first step-up choice here.

A silent chest indicates such severe airway obstruction that airflow is insufficient to generate audible wheeze, and it is a recognized marker of life-threatening asthma requiring immediate aggressive treatment and senior/critical care involvement. Tachypnea, tachycardia, and inability to complete sentences are features of a severe (not life-threatening) exacerbation. Life-threatening features also include a silent chest, cyanosis, exhaustion, confusion, bradycardia or hypotension, and a peak flow below 33% of predicted.

• A. A heart rate above 110/min is a marker of a severe exacerbation, not specifically life-threatening.
• B. A respiratory rate above 25/min is a marker of a severe exacerbation, not specifically life-threatening.
• C. Inability to complete sentences in one breath is a marker of a severe exacerbation, not specifically life-threatening.

Montelukast is a selective antagonist of the cysteinyl leukotriene type 1 (CysLT1) receptor, blocking the effects of leukotrienes released from mast cells and eosinophils that cause bronchoconstriction, mucus secretion, and airway inflammation. This reduces bronchospasm and airway inflammation, making it useful as an add-on controller, particularly in patients with allergic or exercise-induced asthma. It does not act through adrenergic receptors, phosphodiesterase inhibition, or direct mast cell membrane stabilization, which are mechanisms of other drug classes.

• A. Mast cell membrane stabilization describes the mechanism of cromolyn sodium, not montelukast.
• B. Phosphodiesterase-4 inhibition describes the mechanism of drugs such as roflumilast, not montelukast.
• D. Beta-2 receptor blockade would cause bronchoconstriction and is the opposite of a therapeutic asthma mechanism.

Long-term systemic corticosteroid use causes osteoporosis primarily through direct suppression of osteoblast function and promotion of osteoblast and osteocyte apoptosis, together with increased osteoclastic bone resorption, resulting in reduced bone formation and accelerated bone loss. This is why patients on chronic oral corticosteroids require monitoring of bone mineral density and consideration of calcium, vitamin D, and bisphosphonate prophylaxis. Hyperglycemia and electrolyte disturbances are recognized steroid side effects but do not directly explain the bone density loss described.

• B. Corticosteroids do not act by increasing parathyroid hormone receptor density on osteoclasts; this is not an established mechanism.
• C. Hypokalemia is a recognized steroid side effect but is not the mechanism underlying corticosteroid-induced bone loss.
• D. Hyperglycemia from steroids contributes to several complications but is not the direct mechanism of steroid-induced osteoporosis.

Exercise-induced bronchoconstriction is prevented by taking a short-acting beta-2 agonist (SABA) 10-15 minutes before exercise, which relaxes airway smooth muscle and blunts the bronchoconstrictive response to hyperventilation of cool, dry air. This is effective for a single bout of exercise and is the first-line pretreatment per GINA guidelines. Daily controller therapy escalation is reserved for patients with frequent or severe EIB despite pretreatment, not for isolated exercise symptoms in an otherwise well-controlled asthmatic. Oral corticosteroids have no role in routine EIB prophylaxis.

• A. Stepping up to high-dose ICS is not indicated for a patient already well controlled with infrequent, exercise-only symptoms.
• B. Montelukast must be taken daily (or at least 2 hours before exercise) for benefit; taking it only on non-exercise days gives no protection and is used as an alternative/add-on, not as the first choice here.
• D. Oral corticosteroids are not used for routine pretreatment of EIB; they are reserved for severe exacerbations.

This patient has low symptom burden (mMRC 0-1, CAT under 10) and only one moderate exacerbation not requiring hospitalization in the past year, placing him in GOLD group A. Initial therapy for group A is a single long-acting bronchodilator, either a LAMA or a LABA. Dual bronchodilator therapy (LAMA/LABA) is reserved for group B (high symptoms, low exacerbation risk) or group E. Triple therapy with ICS is reserved for group E patients with eosinophilia or features suggesting an asthma overlap, not for low-risk, low-symptom patients.

• A. Inhaled corticosteroid monotherapy is not recommended in COPD at any stage due to lack of benefit and pneumonia risk when used alone.
• C. Dual bronchodilator is the initial choice for group B (high symptom burden) or group E, not group A.
• D. Triple therapy including ICS is reserved for group E with exacerbation risk features, which this patient does not meet.

Alpha-1 antitrypsin (AAT) normally inhibits neutrophil elastase in the lung, protecting alveolar elastin from proteolytic degradation. In AAT deficiency (commonly the PiZZ genotype), misfolded AAT polymerizes and accumulates in hepatocytes (causing liver disease) while failing to reach the lung in adequate amounts, leaving neutrophil elastase unopposed. This leads to progressive destruction of alveolar walls, producing panacinar emphysema that characteristically affects the lower lung zones and occurs at an early age, often in non-smokers or with accelerated course in smokers. This contrasts with smoking-related centriacinar emphysema, which predominantly affects the upper lobes.

• A. AAT deficiency is not an autoimmune disease and does not involve antibody-mediated pneumocyte destruction.
• B. Eosinophilic airway inflammation with mucus hypersecretion describes asthma or eosinophilic bronchitis, not the mechanism of AAT deficiency emphysema.
• C. Amyloid deposition is not the mechanism of AAT deficiency; AAT deficiency involves misfolded protein polymers retained in the liver, not amyloid in the lung.

According to the Anthonisen criteria, antibiotics are indicated in a COPD exacerbation when at least two of the three cardinal symptoms are present: increased dyspnea, increased sputum volume, and increased sputum purulence. This patient has all three, meeting a strong indication for antibiotic therapy regardless of fever or chest X-ray findings, since the absence of consolidation does not exclude a bacterial trigger of the exacerbation. Empiric antibiotics (such as amoxicillin-clavulanate, a macrolide, or a doxycycline depending on local resistance patterns) should be started without waiting for culture results, as exacerbations are often treated empirically.

• B. Fever is not part of the Anthonisen criteria and its absence does not rule out a bacterial exacerbation.
• C. Repeating imaging and delaying treatment is unnecessary when the Anthonisen criteria for antibiotic therapy are already met.
• D. Antibiotics in exacerbations are started empirically; waiting for culture results delays appropriate treatment and cultures are not routinely required to initiate therapy.

In patients with COPD exacerbation, particularly those at risk of chronic hypercapnia, the recommended target oxygen saturation is 88-92%, titrated using controlled devices such as a Venturi mask with arterial blood gas monitoring. Over-oxygenation in COPD can worsen hypercapnia by abolishing hypoxic respiratory drive, worsening ventilation-perfusion mismatch, and causing the Haldane effect, potentially precipitating hypercapnic respiratory failure. A target of 94-98%, appropriate for most acutely ill patients without hypercapnic risk, is too high for COPD patients and risks oxygen-induced hypercapnia.

• A. This target is too low and would leave the patient significantly hypoxemic.
• B. This is the standard target for most acutely unwell patients but is too high for COPD patients at risk of hypercapnic respiratory failure.
• C. Saturations above 98% reflect excessive oxygen administration and significantly increase the risk of CO2 retention in COPD.

Non-invasive ventilation (NIV), typically bilevel positive airway pressure, is indicated in acute COPD exacerbations with persistent respiratory acidosis (pH <7.35) and hypercapnia (PaCO2 >45 mmHg) despite optimal initial medical therapy, in an alert patient able to protect the airway. NIV reduces work of breathing, improves alveolar ventilation, and has been shown to reduce the need for intubation, mortality, and hospital stay in this setting. Invasive ventilation is reserved for NIV failure, inability to tolerate NIV, impaired consciousness, or copious secretions. Increasing oxygen beyond the controlled target would risk worsening hypercapnia and does not address the acidosis.

• A. Aminophylline has a limited role and significant toxicity; it is not the next step when NIV is indicated for respiratory acidosis.
• C. Intubation is reserved for NIV failure or contraindications to NIV; this alert, protecting-airway patient should first trial NIV.
• D. Raising oxygen saturation above the controlled target risks worsening hypercapnia and does not treat the underlying ventilatory failure.